ELOXX PHARMACEUTICALS, INC. (ELOX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 63.39M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | $63.39M | (m) |
| 2026-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | $8.50M | (m) |
| 2025-12-31 | (m) | (m) | $1.00M | $0.00 | (m) | (m) | $5.27M | (m) |
| 2024-12-31 | (m) | (m) | $6.52M | $0.00 | (m) | (m) | $2.98M | (m) |
| 2023-12-31 | (m) | (m) | $2.22M | $1.61M | (m) | (m) | $1.71M | (m) |
| 2023-09-30 | (m) | (m) | $2.82M | $2.62M | (m) | (m) | $6.04M | (m) |
| 2023-06-30 | (m) | (m) | $2.28M | $3.33M | (m) | (m) | $5.99M | (m) |
| 2023-03-31 | (m) | (m) | $1.54M | $4.03M | (m) | (m) | $7.20M | (m) |
| 2022-12-31 | (m) | (m) | $3.98M | $8.56M | (m) | (m) | $21.12M | (m) |
| 2022-09-30 | (m) | (m) | $2.53M | $9.86M | (m) | (m) | $26.88M | (m) |
| 2022-06-30 | (m) | (m) | $1.13M | $11.13M | (m) | (m) | $32.94M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $12.12M | (m) | (m) | $43.62M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $12.00M | (m) | (m) | $45.14M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $11.91M | (m) | (m) | $55.38M | (m) |
| 2021-06-30 | (m) | (m) | $5.69M | $3.64M | (m) | (m) | $60.61M | (m) |
| 2021-03-31 | (m) | (m) | $5.56M | $4.91M | (m) | (m) | $20.37M | (m) |
| 2020-12-31 | (m) | (m) | $5.24M | $6.38M | (m) | (m) | $26.48M | (m) |
| 2020-09-30 | (m) | (m) | $4.92M | $7.82M | (m) | (m) | $32.94M | (m) |
| 2020-06-30 | (m) | (m) | $5.15M | $8.70M | (m) | $37.12M | $39.92M | (m) |
| 2020-03-31 | (m) | (m) | $4.77M | $9.38M | (m) | $43.96M | $47.04M | (m) |
| 2019-12-31 | (m) | (m) | $4.34M | $10.50M | (m) | $56.28M | $58.95M | (m) |
| 2019-09-30 | (m) | (m) | $3.49M | $11.19M | (m) | $64.94M | $68.06M | (m) |
| 2019-06-30 | (m) | (m) | $2.23M | $12.31M | (m) | $76.30M | $79.04M | (m) |
| 2019-03-31 | (m) | (m) | $984.00K | $13.41M | (m) | $53.50M | $56.89M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |